Similar articles for PMID: 11741936

Year	Number of Results
1988	1
1993	1
1994	1
1995	2
1996	6
1997	1
1998	5
1999	4
2000	4
2001	8
2002	10
2003	3
2004	6
2005	1
2006	9
2007	5
2008	4
2009	8
2010	7
2011	4
2012	5
2013	3
2014	2
2015	2
2016	3
2017	2
2018	2
2019	3
2020	2
2021	3
2024	0

1

Amino acid substitutions in Gag protein at non-cleavage sites are indispensable for the development of a high multitude of HIV-1 resistance against protease inhibitors.

Gatanaga H, Suzuki Y, Tsang H, Yoshimura K, Kavlick MF, Nagashima K, Gorelick RJ, Mardy S, Tang C, Summers MF, Mitsuya H. Gatanaga H, et al. J Biol Chem. 2002 Feb 22;277(8):5952-61. doi: 10.1074/jbc.M108005200. Epub 2001 Dec 10. J Biol Chem. 2002. PMID: 11741936 Free article.

2

Non-cleavage site gag mutations in amprenavir-resistant human immunodeficiency virus type 1 (HIV-1) predispose HIV-1 to rapid acquisition of amprenavir resistance but delay development of resistance to other protease inhibitors.

Aoki M, Venzon DJ, Koh Y, Aoki-Ogata H, Miyakawa T, Yoshimura K, Maeda K, Mitsuya H. Aoki M, et al. J Virol. 2009 Apr;83(7):3059-68. doi: 10.1128/JVI.02539-08. Epub 2009 Jan 28. J Virol. 2009. PMID: 19176623 Free PMC article.

3

Changes in human immunodeficiency virus type 1 Gag at positions L449 and P453 are linked to I50V protease mutants in vivo and cause reduction of sensitivity to amprenavir and improved viral fitness in vitro.

Maguire MF, Guinea R, Griffin P, Macmanus S, Elston RC, Wolfram J, Richards N, Hanlon MH, Porter DJ, Wrin T, Parkin N, Tisdale M, Furfine E, Petropoulos C, Snowden BW, Kleim JP. Maguire MF, et al. J Virol. 2002 Aug;76(15):7398-406. doi: 10.1128/jvi.76.15.7398-7406.2002. J Virol. 2002. PMID: 12097552 Free PMC article.

4

Amino acid insertions near Gag cleavage sites restore the otherwise compromised replication of human immunodeficiency virus type 1 variants resistant to protease inhibitors.

Tamiya S, Mardy S, Kavlick MF, Yoshimura K, Mistuya H. Tamiya S, et al. J Virol. 2004 Nov;78(21):12030-40. doi: 10.1128/JVI.78.21.12030-12040.2004. J Virol. 2004. PMID: 15479842 Free PMC article. Clinical Trial.

5

GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.

Koh Y, Das D, Leschenko S, Nakata H, Ogata-Aoki H, Amano M, Nakayama M, Ghosh AK, Mitsuya H. Koh Y, et al. Antimicrob Agents Chemother. 2009 Mar;53(3):997-1006. doi: 10.1128/AAC.00689-08. Epub 2008 Oct 27. Antimicrob Agents Chemother. 2009. PMID: 18955518 Free PMC article.

6

Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process the Gag polyprotein precursor aberrantly.

Resch W, Ziermann R, Parkin N, Gamarnik A, Swanstrom R. Resch W, et al. J Virol. 2002 Sep;76(17):8659-66. doi: 10.1128/jvi.76.17.8659-8666.2002. J Virol. 2002. PMID: 12163585 Free PMC article.

7

Natural variation in HIV-1 protease, Gag p7 and p6, and protease cleavage sites within gag/pol polyproteins: amino acid substitutions in the absence of protease inhibitors in mothers and children infected by human immunodeficiency virus type 1.

Barrie KA, Perez EE, Lamers SL, Farmerie WG, Dunn BM, Sleasman JW, Goodenow MM. Barrie KA, et al. Virology. 1996 May 15;219(2):407-16. doi: 10.1006/viro.1996.0266. Virology. 1996. PMID: 8638406 Free article.

8

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.

Nijhuis M, van Maarseveen NM, Lastere S, Schipper P, Coakley E, Glass B, Rovenska M, de Jong D, Chappey C, Goedegebuure IW, Heilek-Snyder G, Dulude D, Cammack N, Brakier-Gingras L, Konvalinka J, Parkin N, Kräusslich HG, Brun-Vezinet F, Boucher CA. Nijhuis M, et al. PLoS Med. 2007 Jan;4(1):e36. doi: 10.1371/journal.pmed.0040036. PLoS Med. 2007. PMID: 17227139 Free PMC article.

9

Contribution of Gag and Protease to HIV-1 Phenotypic Drug Resistance in Pediatric Patients Failing Protease Inhibitor-Based Therapy.

Giandhari J, Basson AE, Sutherland K, Parry CM, Cane PA, Coovadia A, Kuhn L, Hunt G, Morris L. Giandhari J, et al. Antimicrob Agents Chemother. 2016 Mar 25;60(4):2248-56. doi: 10.1128/AAC.02682-15. Print 2016 Apr. Antimicrob Agents Chemother. 2016. PMID: 26833162 Free PMC article. Clinical Trial.

10

Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its Gag substrate cleavage sites.

Zhang YM, Imamichi H, Imamichi T, Lane HC, Falloon J, Vasudevachari MB, Salzman NP. Zhang YM, et al. J Virol. 1997 Sep;71(9):6662-70. doi: 10.1128/JVI.71.9.6662-6670.1997. J Virol. 1997. PMID: 9261388 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

106 results

Results by year